ICER Releases Two Draft Reports on Obeticholic Acid

The Institute for Clinical and Economic Review (ICER) recently released two Draft Evidence Reports assessing the comparative clinical effectiveness and value of obeticholic acid. Learn more about its use for primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) here. (Source: ICER, 5/25/16)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… July 22, 2019
ICER Outlines Planned Review of Non-Alcoholic Steatohepatitis… November 1, 2019
Biomarkers and Companion diagnostics: Payer Insights September 26, 2019
Pharmerit Expands Market Access Support in Asia January 17, 2019
NASH Drugs Could Face Payer Roadblocks May 18, 2019
The Growing Influence of the Institute of Clinical and… November 21, 2019
Leveraging Technology to Reduce Costs in Clinical Trials June 30, 2019